Empagliflozin-Associated Fournier Gangrene
- PMID: 34228656
- DOI: 10.1097/MJT.0000000000001101
Empagliflozin-Associated Fournier Gangrene
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
-
- Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014;104:297–322.
-
- Cefalu WT, Riddle MC. SLGT2 inhibitors: the latest new kids on the block. Diabetes Care. 2015;38:352–354.
-
- Puckrin R, Saltiel MP, Reynier P, et al. SGLT2 inhibitors and the risk of infections: a systematic review and meta analysis of randomized controlled trials. Acta Diabetol. 2018;55:503–514.
-
- Eke N. Fournier's gangrene: a review of 1726 cases. Br J Surg. 2000;87:718–728.
-
- Semins MJ, Shore AD, Makary MA, et al. The impact of obesity on urinary tract infection risk. Urology. 2012;79:266–269.
LinkOut - more resources
Full Text Sources